Abstract
Arterial stiffness is the most important cause of increasing systolic and pulse pressure, and for decreasing diastolic pressure with ageing. Many measures can be applied to quantify arterial stiffness, but all are approximations only, on account of the nonhomogenous structure of the arterial wall, its variability in different locations, at different levels of distending pressure, and with changes in smooth muscle tone. This article summarizes those indices with a focus on newer non-invasive methods and provides an overview of physiological, pathological and pharmacological influences on arterial hemodynamics. In the near future, the ability to detect and monitor subclinical arterial damage will improve cardiovascular risk stratification and act as a better guide in assessing the efficacy of therapeutic interventions than monitoring blood pressure alone. However, large-scale clinical trials are needed to prove the hypothesis that treatment of these new therapeutic targets will translate into clinical benefit, expressed in cardiovascular events or even mortality.
Keywords: arterial stiffness, cardiovascular drugs, arterial hemodynamics, arterial physiology
Current Pharmaceutical Design
Title: Arterial Stiffness and Cardiovascular Drugs
Volume: 9 Issue: 13
Author(s): Thomas Weber, Johann Auer, Geza Eisserer, Robert Berent, Bernd Eber and Michael F. O´Rourke
Affiliation:
Keywords: arterial stiffness, cardiovascular drugs, arterial hemodynamics, arterial physiology
Abstract: Arterial stiffness is the most important cause of increasing systolic and pulse pressure, and for decreasing diastolic pressure with ageing. Many measures can be applied to quantify arterial stiffness, but all are approximations only, on account of the nonhomogenous structure of the arterial wall, its variability in different locations, at different levels of distending pressure, and with changes in smooth muscle tone. This article summarizes those indices with a focus on newer non-invasive methods and provides an overview of physiological, pathological and pharmacological influences on arterial hemodynamics. In the near future, the ability to detect and monitor subclinical arterial damage will improve cardiovascular risk stratification and act as a better guide in assessing the efficacy of therapeutic interventions than monitoring blood pressure alone. However, large-scale clinical trials are needed to prove the hypothesis that treatment of these new therapeutic targets will translate into clinical benefit, expressed in cardiovascular events or even mortality.
Export Options
About this article
Cite this article as:
Weber Thomas, Auer Johann, Eisserer Geza, Berent Robert, Eber Bernd and O´Rourke F. Michael, Arterial Stiffness and Cardiovascular Drugs, Current Pharmaceutical Design 2003; 9 (13) . https://dx.doi.org/10.2174/1381612033455080
DOI https://dx.doi.org/10.2174/1381612033455080 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Artificial Intelligence Approaches for Rational Drug Design and Discovery
Current Pharmaceutical Design Histamine-Dependent and -Independent Hypersensitivity Reactions to Contrast Media: The Impact of Antihistamines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial: Bioengineering, Clinical and Therapeutical Trends in Transcatheter Aortic Valve Implantation
Current Pharmaceutical Design Immunomodulatory Properties of Farnesoids: The New Steroids?
Current Medicinal Chemistry Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology The Role of Neuropeptides and Neurohormones in Neurogenic Cardiac Arrhythmias
Current Drug Targets - Cardiovascular & Hematological Disorders Subject Index To Volume 2
Current Respiratory Medicine Reviews Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Covid-19: An Update on Clinical Features, Diagnosis, and Treatment Strategies
Coronaviruses Prostacyclin Synthase Gene: Implication and Prevention of Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Evaluation of Serine Protease Inhibitors as Potent FVIIa-sTF Inhibitors in the Blood Coagulation Cascade
Letters in Drug Design & Discovery Virtual Screening Against Obesity
Current Medicinal Chemistry Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Antithrombotic Therapy for Transcatheter Valvular Interventions: A Revisit
Current Vascular Pharmacology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Artemisia Species as Potential Weapon Against Agents and Agricultural Pests
Current Biotechnology Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry